CD19 and neoplasm: They showed that the ADR-expressing CAR T cells can successfully evade immune rejection and achieve sustained tumor eradication in mouse models of allogeneic T cell therapy of hematopoietic (CD19 CAR) and solid (GD2 CAR) cancers.